Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
These findings help explain how relapse-triggering memories can persist alongside those that support recovery
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio
Drugmaker taps 1 million retail touchpoints, quick commerce and modern trade to expand ingredient-led skincare franchise
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
The approach, which could significantly reduce the number of rats used in certain dose-range finding studies
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
